MX2020005041A - Agonistas parciales de interleucina-2. - Google Patents

Agonistas parciales de interleucina-2.

Info

Publication number
MX2020005041A
MX2020005041A MX2020005041A MX2020005041A MX2020005041A MX 2020005041 A MX2020005041 A MX 2020005041A MX 2020005041 A MX2020005041 A MX 2020005041A MX 2020005041 A MX2020005041 A MX 2020005041A MX 2020005041 A MX2020005041 A MX 2020005041A
Authority
MX
Mexico
Prior art keywords
muteins
interleukin
partial agonists
sub
useful
Prior art date
Application number
MX2020005041A
Other languages
English (en)
Inventor
Christopher K Garcia
Sonia S Majri
Caleb R Glassman
Leon Lih- Ren Su
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of MX2020005041A publication Critical patent/MX2020005041A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

En este documento se proporcionan, entre otras cosas, muteínas de interleucina 2 (IL-2) de humano o variantes de las mismas. En particular, en este documento se proporcionan muteínas de IL-2 que tienen una capacidad de unión disminuida para IL-2R?. Tales muteínas de IL-2 son útiles, por ejemplo, como agonista parcial de IL-2 en aplicaciones donde es útil la reducción o inhibición de una o más funciones de IL-2 y/o IL-15 (por ejemplo, en el tratamiento de enfermedades o afecciones autoinmunes). También se proporcionan ácidos nucleicos que codifican tales muteínas de IL-2, métodos para hacer tales muteínas de IL-2, composiciones farmacéuticas que incluyen tales muteínas de IL-2 y métodos de tratamiento utilizando tales composiciones farmacéuticas.
MX2020005041A 2017-11-21 2018-11-20 Agonistas parciales de interleucina-2. MX2020005041A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762589497P 2017-11-21 2017-11-21
PCT/US2018/062122 WO2019104092A1 (en) 2017-11-21 2018-11-20 Partial agonists of interleukin-2

Publications (1)

Publication Number Publication Date
MX2020005041A true MX2020005041A (es) 2020-10-12

Family

ID=66631137

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005041A MX2020005041A (es) 2017-11-21 2018-11-20 Agonistas parciales de interleucina-2.

Country Status (13)

Country Link
US (2) US20200299349A1 (es)
EP (1) EP3713592A4 (es)
JP (1) JP7464278B2 (es)
KR (1) KR20200086722A (es)
CN (1) CN111615396A (es)
AU (2) AU2018372167B2 (es)
BR (1) BR112020009920A2 (es)
CA (1) CA3082904A1 (es)
IL (1) IL274723A (es)
MX (1) MX2020005041A (es)
RU (1) RU2020120145A (es)
SG (1) SG11202004581PA (es)
WO (1) WO2019104092A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10961310B2 (en) 2017-03-15 2021-03-30 Pandion Operations, Inc. Targeted immunotolerance
BR112019024127A2 (pt) 2017-05-24 2020-06-23 Pandion Therapeutics, Inc. Imunotolerância alvejada
JP2020529976A (ja) 2017-08-03 2020-10-15 シンソークス，インク． 自己免疫疾患の処置のためのサイトカイン抱合体
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
CN114679909A (zh) 2019-05-20 2022-06-28 潘迪恩运营公司 MAdCAM靶向的免疫耐受
CN110642934B (zh) * 2019-09-10 2022-08-23 中国医学科学院北京协和医院 靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用
KR20220116513A (ko) 2019-12-20 2022-08-23 리제너론 파아마슈티컬스, 인크. 신규 il2 작용제 및 이의 사용 방법
CN115315436A (zh) 2020-01-10 2022-11-08 明峰治疗股份公司 修饰的il-2多肽及其用途
US20230076768A1 (en) 2020-01-14 2023-03-09 Synthekine, Inc. IL2 Orthologs and Methods of Use
KR102653906B1 (ko) * 2020-01-14 2024-04-03 신테카인, 인크. 편향된 il2 뮤테인 방법 및 조성물
US20230226203A1 (en) * 2020-06-18 2023-07-20 Proviva Therapeutics (Hong Kong) Limited Activatable procytokines
AR125263A1 (es) * 2021-03-31 2023-06-28 Hanmi Pharm Ind Co Ltd Nuevo conjugado de análogo de il-2 inmunoestimulante y su método de preparación
AU2022307460A1 (en) 2021-07-09 2024-01-04 Bright Peak Therapeutics Ag Checkpoint inhibitors conjugated to il-2, and uses thereof
WO2023281480A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Conjugates of checkpoint inhibitors with il-2, and uses thereof
US20230201364A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Antibody conjugates and manufacture thereof
US20230201365A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Modified cd20 antibodies and uses thereof
WO2023161857A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Bifunctional cytokine compositions
WO2023200796A1 (en) * 2022-04-13 2023-10-19 The Regents Of The University Of California Immune cell inhibition by immune checkpoint engagers
WO2024086739A1 (en) 2022-10-20 2024-04-25 Synthekine, Inc. Methods and compositions of il12 muteins and il2 muteins

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
RS20050501A (en) * 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polymer conjugates of cytokines,chemokines,growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
JP2007527242A (ja) * 2004-03-05 2007-09-27 カイロン コーポレーション 治療剤の患者耐容性を予測するためのインビトロ試験システム
JP2008528621A (ja) * 2005-01-27 2008-07-31 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド 腎細胞ガンを処置するための方法
US8906356B2 (en) * 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
RS61854B1 (sr) * 2010-11-12 2021-06-30 Nektar Therapeutics Konjugati il-2 dela i polimera
US9428567B2 (en) * 2010-12-22 2016-08-30 The Board Of Trustees Of The Leland Stanford Junior University Antagonists of interleukin-2 receptor
CN111423513A (zh) * 2014-02-06 2020-07-17 豪夫迈·罗氏有限公司 白介素-2融合蛋白和其用途
EP3134102B1 (en) * 2014-04-24 2019-07-03 The Board of Trustees of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2

Also Published As

Publication number Publication date
AU2024200355A1 (en) 2024-03-21
KR20200086722A (ko) 2020-07-17
US20210269498A1 (en) 2021-09-02
BR112020009920A2 (pt) 2020-12-15
EP3713592A4 (en) 2022-01-12
IL274723A (en) 2020-07-30
SG11202004581PA (en) 2020-06-29
WO2019104092A1 (en) 2019-05-31
EP3713592A1 (en) 2020-09-30
US20200299349A1 (en) 2020-09-24
AU2018372167B2 (en) 2023-12-07
CA3082904A1 (en) 2019-05-31
CN111615396A (zh) 2020-09-01
JP7464278B2 (ja) 2024-04-09
JP2021508252A (ja) 2021-03-04
AU2018372167A1 (en) 2020-06-11
RU2020120145A (ru) 2021-12-22

Similar Documents

Publication Publication Date Title
MX2020005041A (es) Agonistas parciales de interleucina-2.
PH12020500241A1 (en) Cytokine conjugates for the treatment of autoimmune diseases
CN106659757A8 (zh) 白介素2的超级激动剂、部分激动剂和拮抗剂
MX2021009259A (es) Conjugados de il-2 y metodos de uso del mismo.
PH12020551261A1 (en) Il-15 conjugates and uses thereof
NZ736560A (en) Proteins specific for cd137
MX2020012602A (es) Composiciones bacterianas dise?adas y usos de las mismas.
MX2022005411A (es) COMPUESTOS DE UNIÓN A IL-2RßYC.
MX2022007754A (es) Nuevos agonistas de il2 y metodos de uso de estos.
PH12019500643A1 (en) Antibodies that bind interleukin-2 and uses thereof
MX2010003574A (es) Anticuerpos il-23.
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
MX2022001061A (es) Agentes de interleuquina-2 y usos de los mismos.
MX2022002740A (es) Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
ZA202105285B (en) Antibody against human il-4ra and use thereof
MX2020007945A (es) Proteinas f del rsv estabilizadas y usos de las mismas.
MX2021015160A (es) Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso.
EP4032539A4 (en) IMMUNOCYTOKINE WITH HETERODIMERIC PROTEIN COMPLEX BASED ON IL-15/IL-15R-ALPHA
EA201991951A1 (ru) Низковязкие высококонцентрированные составы на основе эволокумаба и способы их получения
PH12021551100A1 (en) Dried biological compositions and methods thereof
MX2021015761A (es) Polipeptidos.
MX2021007589A (es) Anticuerpos anti il-36 y procedimientos de uso de estos.
IL283882A (en) Preparations and methods for the treatment of (cutaneous t cell lymphoma (ctcl
MX2021015544A (es) Formulaciones de oxido de polialquileno-asparaginasa y metodos de preparacion y uso del mismo.
MX2021008022A (es) Proteínas heterodiméricas para modular células t gamma delta.